The non-antiretroviral, non-hormonal intravaginal ring developed by the Oak Crest Institute of Science is a multipurpose prevention technology with a 1-to 3-month duration combining two novel, luminally acting active pharmaceutical ingredients: (1) an antiviral with unique mechanisms of action against HSV; and (2) a contraceptive and would be a game-changer product for women who desire non-hormonal contraceptives with prevention of HSV and other sexually transmitted infections in a single product. Gathering end-user feedback early in the design phase will be prioritized. First-in-human trials will evaluate the safety and pharmacokinetics of the multipurpose prevention technology.

For more information, contact: Marc Baum at m.baum@oak-crest.org